EUROPEAN CURRICULUM VITAE FORMAT

PERSONAL INFORMATION

Name	**Giulia Mesiano**
Address	25 A, Via della Fontana 10090 Sangano (Torino, Italy)
E-mail/ mobile phone	giulia.mesiano384@gmail.com / 3498864331
Nationality	Italian
Date of birth	30/08/1984

RESEARCH EXPERIENCE

• Dates	**01/2022-01/2023**
• Name and address of employer	Politecnico di Torino DISAT - Dipartimento Scienza Applicata e Tecnologia
• Occupation or position held	**Post doc Research**
• Main activities and responsibilities	Study of innovative materials and production of M/NEMS and optical devices for ambient-security-agro_alimentary-biomedical applications.

• Dates	**06/2021-12/2021**
• Name and address of employer	FPO (Fondazione del Piemonte per l'Oncologia) IRCCS Candiolo Laboratory of Experimental Cell Therapy
• Occupation or position held	**Post doc Research (co.co.co)**
• Main activities and responsibilities	Antitumor and immunomodulatory role of Interferons, molecular targeted therapy and immunotherapy in gastrointestinal stromal tumors.

• Dates	**01/2018-12/2018**
• Name and address of employer	FPO (Fondazione del Piemonte per l'Oncologia) Laboratory of Experimental Cell Therapy, IRCCS Candiolo.
• Occupation or position held	**Post doc fellowship granted by AIRC (co.co.co)**
• Main activities and responsibilities	Integrated immunotherapy of solid tumors (Sarcoma, Melanoma). Preclinical study to investigate the potential efficacy of T-cells as adoptive immunotherapy and their synergism whit chemotherapies and molecular targeted therapies against solid tumors.

• Dates	**01/2016-12/2017**
• Name and address of employer	FPO (Fondazione del Piemonte per l'Oncologia) Laboratory of Experimental Cell Therapy, IRCCS Candiolo.
• Occupation or position held	**Post doc fellowship granted by 5 per mille Ministero della Salute anno 2012 (co.co.co)**
• Main activities and responsibilities	T-cell adoptive immunotherapy of solid tumors: preclinical study to investigate the potential efficacy of Cytokine-Induced Killer (CIK) cells as adoptive immunotherapy for sarcoma cancer cells resistant to chemotherapies and molecular targeted therapies including putative cancer stem cells.

• Dates	**01/2014-12/2015**
• Name and address of employer	FPO (Fondazione del Piemonte per l'Oncologia) Medical Oncology Laboratory, IRCCS Candiolo.
• Occupation or position held	**Post doc fellowship granted by AIRC**

• Main activities and responsibilities	T-cell adoptive immunotherapy of solid tumors: preclinical study to investigate the potential efficacy of Cytokine-Induced Killer (CIK) cells as adoptive immunotherapy for bone and soft tissue sarcomas.
• Dates	**12/2008- 12/2009**
• Name and address of employer	Professor Massimo Aglietta Medical Oncology Laboratory, IRCCS Candiolo.
• Occupation or position held	**ADISCO (Italian Association of Donor Umbilical Cord Blood) fellowship for research training**
• Main activities and responsibilities	Ex vivo Expansion and Modulation of Regulatory T cells with Tumor-Specific T Lymphocytes: Implications for strategies of Adoptive Immunotherapy after Hematopoietic Stem Cell Transplantation

EDUCATION AND TRAINING

• Dates (from)	**06/2014**
Name and type of organisation providing education and training	University of Pavia
Title of qualification awarded	**Obtaining certification to exercise the profession of biologist**
• Dates (from)	**01/2014 – 12/2015**
Name and type of organisation providing education and training	**AIRC** Associazione Italiana per la Ricerca sul Cancro
Title of qualification awarded	**Winner of two-year fellowship** for the project "Identification and killing of cancer stem cells in mesenchymal tumors by immunotherapy with CIK cells"
• Dates	**01/2011-01/2014**
Name and type of organisation providing education and training	Prof. Massimo Aglietta, Cellular Therapy's Laboratory, Department of Oncology Science, IRCCS Candiolo.
Title of qualification awarded	**PhD in Biomedical Science and Human Oncology (03/2014)**
• Main activities and responsibilities	Main focus of research activity: T-cell adoptive immunotherapy of solid tumors: preclinical study to investigate the potential efficacy of Cytokine-Induced Killer (CIK) cells as adoptive immunotherapy for bone and soft tissue sarcomas.
• Dates	**10/2006-10/2008**
• Name and type of organisation providing education and training	**Master Degree in Medical Biotechnologies** Faculty of Medicine and Surgery, University of Turin- Italy Supervisor: Professor Massimo Aglietta Institute for Cancer Research and Treatment Medical Oncology Laboratory Internal Student Study of biological phenomena underlying the effects of GVHD and GVT after allogeneic transplantation: - p the use of Artificial lentiviral vectors encoding the transgene Foxp3; - analysis of the antitumor activity of CIK strategies of segregation of these two properties.
• Principal subjects/occupational skills covered	Molecular Biology, Biochemistry, Microbiology, Genetics, Immunology, Physiology and human Pathology. **Thesis Title**: "Regulatory T cells generated in vitro as a potential strategy against GVHD induced by transplantation of hematopoietic stem cells" Supervisor: Professor Giovanni Rolla *(Associate Professor, Internal Medicine, Department of Biomedical Sciences and Human Oncology, University of Turin AO Mauriziano's Order)* Tutor: MD Dario Sangiolo 110/110 cum laude The thesis was judged by the Commision "WORTHY OF PRINT" Work drawn from experimental thesis was presented as a poster at the 50th Congress of the American Society of Hematology (ASH 2008).
• Dates	***10/2003-10/2006***
• Name and type of organisation providing education and training	**Bachelor Degree in Biotechnology** Interfaculty school of Biotechnology, University of Turin- Italy Supervisor: Professor Alfredo Brusco

	Internal student at Molecular genetic laboratory Department of Genetics Biology and Biochemistry
• Principal subjects/occupational skills covered	Cellular Biology, Molecular Biology, Biochemistry, Immunology, Microbiology, Chemistry. Thesis Title: "The human genetic diseases associated with mitochondrial DNA gamma polymerase: Autosomal Recessive Ataxias" Supervisor: Prof. Alfredo Brusco 103/110
• Dates	***1998-2003***
• Name and type of organisation providing education and training	Secondary School focusing science "Niccolò Copernico",Turin, Italy
• Principal subjects/occupational skills covered	Science, Physics, Mathematics and Informatics
Mark	81/100
• Title of qualification awarded	**Scientific High school degree**

Personal skills and competences

Mother tongue(s)	**ITALIAN**
Other language(s)	
	ENGLISH
• Reading skills	C1
• Writing skills	B2
Verbal skills	B2
	FRENCH
• Reading skills	B2
• Writing skills	A1
• Verbal skills	B1

SOCIAL SKILLS AND COMPETENCES

Excellent ability to relate with others and team work.
I'm a friendly person, I really like traveling, visiting new places, meet new people and learn reality different from mine. I have always practiced team sports. I played soccer in the role of goalkeeper . This is a role of great responsibility and it is not always easy to play.

TECHNICAL SKILLS

Consolidated experience with ex-vivo expansion and culturing of human lymphocytes. Generation of T cells and Cytokine Induced Killer (CIK) cells and redirection of T and CIK cells.

Deep capacity in in-vitro expansion of tumor cells deriving from different types of human tumor samples.

Consolidated capability in performing cytotoxicity test to investigate potential role of immune effector cells against solid tumors, also in combination with drugs (chemotherapy, molecular targeted therapy, cytokines).

Consolidated experience with ex-vivo manipulation and processing of human surgical tumor biopsies (sarcomas, especially soft tissue and Osteosarcomas) to obtain and stabilize primary cultures (2D, spheroids).

Consolidated expertise in flow-cytometry acquisition and analysis.

Purification of hematopoietic cells from human cord blood, peripheral blood and bone morrow.

Transfection, virus production (lentivirus), transduction of primary cells and cell lines.

Immunohistochemistry; optical/fluorescence microscopy; ELYSPOT and ELISA assays.

General molecular biology techniques, RNA/DNA extraction, PCR, RT-PCR, DNA cloning, cDNA synthesis.

Analysis of cellular functionality through test of proliferation (Mixed Leukocyte Reaction),

Consolidated experience in murine animal models: xenograft mouse model, in-vivo subcutaneous, intraperitoneal, and intravenous injection of drugs and cells.

Competences in clinical trials

Good expertise in specimen processing, transportation and reporting procedures according to

clinical study protocols for clinical trials; achieved the following certificate:
GCP Training Certificate
IATA Training Certificate

INFORMATIC SKILLS AND COMPETENCES

Good knowledge of Windows operative systems.
Experienced with Word, Excel, PowerPoint, Adobe, PhotoShop and other graphical (graphpad prism) and analytical software (summit flow-cytometry).
Good knowledge of database National Center for Biotechnology Information (NCBI) and its software for genome analysis.
Very good knowledge of Microsoft edge and google chrome with daily use as part of current job.

DRIVING LICENCE

B car owner

PUBLICATIONS

- Giorgia Giordano, Alessandra Merlini, Giulio Ferrero , **Giulia Mesiano**, Erika Fiorino , Silvia Brusco, Maria Laura Centomo, Valeria Leuci, Lorenzo D'Ambrosio, Massimo Aglietta, Dario Sangiolo, Giovanni Grignani and Ymera Pignochino.
EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma.
Cells 2021 Oct.

-Leuci V, Donini C, Grignani G, Rotolo R, **Mesiano G**, Fiorino E, Gammaitoni L, D'Ambrosio L, Merlini A, Landoni E, Medico E, Capellero S, Giraudo L, Cattaneo G, Iaia I, Pignochino Y, Basiricò M, Vigna E, Pisacane A, Fagioli F, Ferrone S, Aglietta M, Dotti G, Sangiolo D.
CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes.
Clin Cancer Res. 2020 Dec.

-Mareschi K, Adamini A, Castiglia S, Rustichelli D, Castello L, Mandese A, Leone M, Pinnetta G, **Mesiano G**, Ferrero I, Fagioli F.
Cytokine-Induced Killer (CIK) Cells, In Vitro Expanded under Good Manufacturing Process (GMP) Conditions, Remain Stable over Time after Cryopreservation.
Pharmaceuticals (Basel). 2020 May.

-Castiglia S, Adamini A, Rustichelli D, Castello L, Mareschi K, Pinnetta G, Leone M, Mandese A, Ferrero I, **Mesiano G**, Fagioli F.
Cytokines induced killer cells produced in good manufacturing practices conditions: identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identity.
J Transl Med. 2018 Oct.

-Mesiano G, Grignani G, Fiorino E, Leuci V, Rotolo R, D'Ambrosio L, Salfi C, Gammaitoni L, Giraudo L, Pisacane A, Butera S, Pignochino Y, Basiricó M, Capozzi F, Sapino A, Aglietta M, Sangiolo D.
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.
ONCOIMMUNOLOGY. 2018 Aug.

-Leuci V, Casucci GM, Grignani G, Rotolo R, Rossotti U, Vigna E, Gammaitoni L, **Mesiano G**, Fiorino E, Donini C, Pisacane A, Ambrosio LD, Pignochino Y, Aglietta M, Bondanza A, Sangiolo D. (2018).
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.
Oncoimmunology. 2018 Feb.

-**Mesiano G**, Zini R, Montagner G, Bianchi N, Manfredini R, Chillemi A, Aglietta M, Grignani G, Lampronti I, Fiorino E, Malavasi F, Sangiolo D, Gambari R, Ferrari D.
Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells.
Mol Med. 2017 Aug

-Casnici C, Crotta K, Volpe G, Panuzzo C, Lattuada D, **Mesiano G**, Saglio G, Marelli O.
Specific Monoclonal Antibody Against Bcr/Abl Out-of-Frame Alternative Proteins as Diagnostic Tool in Chronic Myelogenous Leukemia Patients.
Monoclon Antib Immunodiagn Immunother. 2017 Aug.

-Gammaitoni L, Giraudo L, Macagno M, Leuci V, **Mesiano G**, Rotolo R, Sassi F, Sanlorenzo M, Zaccagna A, Pisacane A, Senetta R, Cangemi M, Cattaneo G, Martin V, Coha V, Gallo S, Pignochino Y, Sapino A, Grignani G, Carnevale-Schianca F, Aglietta M, Sangiolo D.
Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells.
Clin Cancer Res. 2017 May.

-Leuci V, Maione F, Rotolo R, Giraudo E, Sassi F, Migliardi G, Todorovic M, Gammaitoni L, Mesiano G, Giraudo L, Luraghi P, Leone F, Bussolino F, Grignani G, Aglietta M, Trusolino L, Bertotti A, Sangiolo D.
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity.
J Transl Med. 2016 May.

-Gammaitoni L, Giraudo L, Leuci V, Mesiano G, Cangemi M, Zaccagna A, Pisacane A, Gallo S, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells.
J Transl Med. 2015.

-Mesiano G, Leuci V, Giraudo L, Gammaitoni L, Carnevale Schianca F, Cangemi M, Rotolo R, Capellero S, Pignochino Y, Grignani G, Aglietta M, Sangiolo D.
Adoptive immunotherapy against sarcomas.
Expert Opin Biol Ther. 2014 Dec.

- Sangiolo D, Mesiano G, Gammaitoni L, Aglietta M, Grignani G.
Activity of cytokine-induced killer cells against bone and soft tissue sarcoma.
Oncoimmunology. 2014 Mar 17.

- Gammaitoni L, Leuci V, Mesiano G, Giraudo L, Todorovic M, Carnevale-Schianca F, Aglietta M, Sangiolo D.
Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective.
Expert Opin Biol Ther.2014 May 16.

-V. Leuci, G. Mesiano, L. Gammaitoni, M. Todorovic, L. Giraudo, F. Carnevale-Schianca, M. Aglietta and D. Sangiolo.
Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy
Anti-Cancer Agents in Medicinal Chemistry, November 2013, Vol. 14.

-D. Sangiolo, G. Mesiano, L. Gammaitoni, V. Leuci, M. Todorovic, L. Giraudo, C. Cammarata, C. Dell'Aglio, L. D'Ambrosio, A. Pisacane, I. Sarotto, S. Miano, I. Ferrero, F. Carnevale-Schianca, Y. Pignochino, F. Sassi, A. Bertotti, W. Piacibello, F. Fagioli, M. Aglietta and G. Grignani.
Cytokine-Induced Killer Cells eradicate Bone and Soft Tissue Sarcomas.
Cancer Research, 2013 October Under printing.

- Gammaitoni L, Giraudo L, Leuci V, Todorovic M, Mesiano G, Picciotto F, Pisacane A, Zaccagna A, Volpe MG, Gallo S, Caravelli D, Giacone E, Venesio T, Balsamo A, Pignochino Y, Grignani G, Carnevale-Schianca F, Aglietta M, Sangiolo D.
Effective Activity of Cytokine Induced Killer Cells against Autologous Metastatic Melanoma including Cells with Stemness Features.
Clinical Cancer Research, 2013 August.

-Todorovic M, Mesiano G, Gammaitoni L, Leuci V, Giraudo Diego L, Cammarata C, Jordaney N, Carnevale-Schianca F, Gallo S, Fagioli F, Piacibello W, Elia AR,Pignochino Y, Dell'aglio C, Grignani G, Cignetti A, Aglietta M, Sangiolo D.
Ex Vivo Allogeneic Stimulation Significantly Improves Expansion of Cytokine-Induced Killer Cells Without Increasing Their Alloreactivity Across HLA Barriers.
Journal of Immunotherapy, 2012 Sep;35(7):579-586.

-G. Mesiano , M. Todorovic, L. Gammaitoni, V. Leuci, L. Giraudo Diego, F. Carnevale-Schianca, F. Fagioli, W. Piacibello, M.Aglietta, D. Sangiolo.
Cytokine Induced Killer (CIK) Cells as Feasible and Effective Adoptive Immunotherapy for the Treatment of Solid Tumors.
Expert Opinion on Biological Therapy, 2012 April.

- Leuci V, Mesiano G, Gammaitoni L, Cammarata C, Capellero S, Todorovic M, Jordaney N, Circosta P, Elia A, Lesnikova M, Georges GE, Piacibello W, Cignetti A, Aglietta M, Sangiolo D.
Transient Proteasome Inhibition as a Strategy to Enhance Lentiviral Transduction of Hematopoietic CD34+ Cells and T Lymphocytes: implications for the use of low viral doses and large-size vectors.
Journal of Biotechnology 2011 Sep;

-Sangiolo D, Mesiano G, Carnevale-Schianca F, Piacibello W, Aglietta M, Cignetti A.
Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation.
Expert Opin Biol Ther. 2009 Jul;9(7):831-40.

I herewith authorize you to process my personal data in compliance with the Law N.675 of 31 December 1996 and legislative decree no. 196 of June 30, 2003